SCHEMBL2562601

SCHEMBL2562601

CCCSc1nc2cc[nH]c2c(=O)n1-c1ccc(OCC(F)(F)F)cc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 1/20 0.51
TSHR P16473 2/20 0.46
APLNR P35414 4/20 0.42
PIK3CD O00329 2/20 0.40
PIK3CB P42338 2/20 0.40
PIK3CG P48736 2/20 0.40
PIK3CA P42336 1/20 0.39
TP53 P04637 5/20 0.39
LMNA P02545 2/20 0.39
PDE11A Q9HCR9 2/20 0.38
PDE7A Q13946 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2561473 0.92 FADS1 (0.49) FADS1TSHRPIK3CDPIK3CBPIK3CG
SCHEMBL2567552 0.91 FADS1 (0.49) FADS1TSHRPIK3CDPIK3CBPIK3CG
SCHEMBL2559985 0.90 FADS1 (0.51) FADS1TSHRAPLNRPIK3CDPIK3CB
SCHEMBL2568025 0.90 FADS1 (0.47) FADS1TSHRAPLNRPIK3CDPIK3CB
SCHEMBL2566441 0.89 FADS1 (0.47) FADS1TSHRPIK3CDPIK3CBPIK3CG
SCHEMBL2565109 0.89 FADS1 (0.47) FADS1TSHRPIK3CDPIK3CBPIK3CG
SCHEMBL2567416 0.89 FADS1 (0.47) FADS1TSHRPIK3CDPIK3CBPIK3CG
SCHEMBL2566907 0.89 FADS1 (0.49) FADS1TSHRAPLNRPIK3CDPIK3CB
SCHEMBL2566139 0.89 FADS1 (0.51) FADS1TSHRAPLNRPIK3CDPIK3CB
SCHEMBL2566541 0.89 FADS1 (0.50) FADS1TSHRAPLNRPIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2382218-A1 DELTA-5-DESATURASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2011-11-02 EP disclosed
WO-2010087467-A1 DELTA-5-DESATURASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-05 WO disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190747-A1 Fused ring compound and use thereof CYP46A1, LTB4R2, PTGES FADS1 140/4885TSHR 4543/4885APLNR 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.